Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Kalaris Therapeutics Inc. (NASDAQ:KLRS) have received a consensus rating of “Moderate Buy” from the nine analysts that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $15.60.

Several analysts recently commented on KLRS shares. Morgan Stanley initiated coverage on Kalaris Therapeutics in a research note on Thursday, April 16th. They set an “overweight” rating and a $14.00 price objective on the stock. TD Cowen assumed coverage on Kalaris Therapeutics in a research note on Monday, June 15th. They issued a “buy” rating for the company. Wall Street Zen downgraded Kalaris Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, June 14th. Weiss Ratings raised Kalaris Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday. Finally, Wedbush began coverage on Kalaris Therapeutics in a research report on Thursday, May 14th. They issued an “outperform” rating and a $17.00 price objective for the company.

Insiders Place Their Bets

In other news, Director Srinivas Akkaraju bought 244,300 shares of the stock in a transaction on Wednesday, May 20th. The stock was purchased at an average price of $4.83 per share, for a total transaction of $1,179,969.00. Following the acquisition, the director owned 2,224,147 shares in the company, valued at approximately $10,742,630.01. This trade represents a 12.34% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 68.10% of the company’s stock.

Institutional Investors Weigh In On Kalaris Therapeutics

Institutional investors have recently bought and sold shares of the company. XTX Topco Ltd bought a new stake in shares of Kalaris Therapeutics in the second quarter worth $65,000. Johnson Financial Group Inc. bought a new position in Kalaris Therapeutics in the third quarter valued at $58,000. Bridgeway Capital Management LLC acquired a new stake in Kalaris Therapeutics in the 3rd quarter valued at $130,000. Woodline Partners LP acquired a new stake in Kalaris Therapeutics in the 3rd quarter valued at $1,394,000. Finally, WHI TRUST Co LLC acquired a new stake in Kalaris Therapeutics in the 4th quarter valued at $823,000. Institutional investors own 66.05% of the company’s stock.

Kalaris Therapeutics Stock Performance

NASDAQ:KLRS traded down $0.05 on Friday, hitting $4.44. 10,280 shares of the stock were exchanged, compared to its average volume of 66,382. The stock has a market capitalization of $105.63 million, a price-to-earnings ratio of -2.07 and a beta of 0.19. Kalaris Therapeutics has a 52 week low of $2.14 and a 52 week high of $11.88. The company’s 50-day moving average price is $4.70 and its 200 day moving average price is $7.03.

Kalaris Therapeutics (NASDAQ:KLRS) last issued its earnings results on Tuesday, May 12th. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.06. As a group, equities research analysts predict that Kalaris Therapeutics will post -2 earnings per share for the current year.

Kalaris Therapeutics Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.